Atomo Diagnostics Dirección

Dirección controles de criterios 3/4

El CEO de Atomo Diagnostics' es John Kelly , nombrado en Jan 2010, tiene una permanencia de 14.25 años. compensación anual total es A$542.02K, compuesta por 76.9% salario y 23.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.15% de las acciones de la empresa, por valor de A$221.11K. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 4.2 años, respectivamente.

Información clave

John Kelly

Chief Executive Officer (CEO)

AU$542.0k

Compensación total

Porcentaje del salario del CEO	76.9%
Permanencia del CEO	14.3yrs
Participación del CEO	1.2%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 01

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Feb 26

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

Dec 18

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Jul 16

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Kelly en comparación con los beneficios de Atomo Diagnostics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$542k	AU$417k	-AU$10m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$533k	AU$368k	-AU$6m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$6m
Jun 30 2021	AU$467k	AU$372k	-AU$6m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$10m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$611k	AU$298k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$7m
Dec 31 2019	n/a	n/a	-AU$5m
Sep 30 2019	n/a	n/a	-AU$5m
Jun 30 2019	AU$319k	AU$248k	-AU$5m

Compensación vs. Mercado: La compensación total ($USD349.58K) de John está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD289.12K).

Compensación vs. Ingresos: La compensación de John ha aumentado mientras la empresa no es rentable.

CEO

John Kelly

14.3yrs

Permanencia

AU$542,017

Compensación

Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Kelly	Founder	14.3yrs	AU$542.02k	1.15% A$ 228.5k
Chandra Sukumar	Chief Operating Officer	2.1yrs	AU$324.29k	0.027% A$ 5.3k
Jim McMenamy	Head of Business Development & Partnerships of the Americas	2.1yrs	sin datos	sin datos
Anna Tucker	Head of Business Development & Partnerships of Europe	2.1yrs	sin datos	sin datos
Maria Clemente	Company Secretary	1.2yrs	sin datos	sin datos

2.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de AT1 se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Kelly	Founder	14.1yrs	AU$542.02k	1.15% A$ 228.5k
Deborah Neff	Independent Non-Executive Director	2.7yrs	AU$88.33k	sin datos
Cheri Walker	Independent Non-Executive Director	1.5yrs	AU$31.25k	sin datos
Paul Kasian	Independent Non-Executive Director	4.3yrs	AU$70.00k	0.016% A$ 3.1k
John Keith	Independent Non-Executive Chairman	12.4yrs	AU$130.00k	0.51% A$ 101.1k
Ian Boulton	Member of Advisory Board	no data	sin datos	sin datos

4.3yrs

Permanencia media

Junta con experiencia: La junta directiva de AT1 se considera experimentada (4.2 años de antigüedad promedio).

Atomo Diagnostics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

Atomo Diagnostics Limited, Annual General Meeting, Oct 27, 2022

Recent updates

Atomo Diagnostics Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Atomo Diagnostics Limited to Report First Half, 2024 Results on Jan 29, 2024

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

New major risk - Market cap size

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.01 loss in FY 2022)

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

New major risk - Share price stability

Atomo Diagnostics Limited to Report Q4, 2023 Results on Jul 31, 2023

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.004 loss in 1H 2022)

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Atomo Diagnostics Limited, Annual General Meeting, Oct 27, 2022

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Forecast breakeven date pushed back to 2024

Atomo Diagnostics Limited Expands Executive Team

No longer forecast to breakeven

First half 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$0.31

Atomo Diagnostics Limited to Report First Half, 2022 Results on Feb 21, 2022

Atomo Diagnostics Limited Receives Approval for its Covid-19 Antigen Test in NZ

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2021 earnings released

Consensus revenue estimates fall to AU$7.20m

Forecast breakeven pushed back to 2023

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to AU$9.60m

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.008 loss in 1H 2020)

Revenue and earnings beat expectations

New 90-day low: AU$0.28

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

New 90-day low: AU$0.29

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

New 90-day low: AU$0.30

Atomo Diagnostics Limited Receives TGA Approval for Atomorapid HIV (1&2) Test

Atomo Diagnostics Limited Receives TGA Approval for Covid19 Antigen Test

New 90-day low: AU$0.33

Atomo Diagnostics Limited Expands Its Existing COVID-19 Rapid Test Partnership with Access Bio LLC

Atomo Diagnostics Limited Enters into an Agreement DIVOC Laboratories to Launch its COVID-19 Antibody Test in the Indian Market

Full year earnings released - AU$0.026 loss per share

Atomo Diagnostics Limited to Report Fiscal Year 2020 Final Results on Nov 02, 2020

New 90-day high - AU$0.45

Atomo Diagnostics Limited to Report Fiscal Year 2020 Results on Aug 31, 2020

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media